The group's principal activity is to develop and intend to commercialize innovative products to treat and prevent allergies, infectious diseases and chronic inflammatory diseases using versatile, proprietary approaches that alter immune system responses in highly specific ways. The clinical development programs are based on immunostimulatory sequences, which are short dna, which are short dna sequences that enhance the ability of the immune system to fight disease and control chronic inflammation. As on 24-Feb-2004, the group completed initial public offering.
